within Pharmacolibrary.Drugs.ATC.N;

model N05CH01_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 38.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,
    adminCount     = 1,
    Vd             = 0.0502,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Melatonin is an endogenous hormone produced by the pineal gland involved in the regulation of circadian rhythms and sleep-wake cycles. As a drug, melatonin is primarily used to treat insomnia, jet lag, and circadian rhythm sleep disorders, and is available as an over-the-counter supplement in many countries. It is generally considered safe with limited adverse effects and is not approved as a prescription medication in most regions, but is widely used for sleep-related complaints.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following intravenous administration of 10 mg melatonin in healthy adult volunteers (both sexes).</p><h4>References</h4><ol><li><p>Lalanne, S, et al., &amp; Tordjman, S (2021). Melatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder. <i>International journal of molecular sciences</i> 22(3) –. DOI:<a href=&quot;https://doi.org/10.3390/ijms22031490&quot;>10.3390/ijms22031490</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33540815/&quot;>https://pubmed.ncbi.nlm.nih.gov/33540815</a></p></li><li><p>Harpsøe, NG, et al., &amp; Rosenberg, J (2015). Clinical pharmacokinetics of melatonin: a systematic review. <i>European journal of clinical pharmacology</i> 71(8) 901–909. DOI:<a href=&quot;https://doi.org/10.1007/s00228-015-1873-4&quot;>10.1007/s00228-015-1873-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26008214/&quot;>https://pubmed.ncbi.nlm.nih.gov/26008214</a></p></li><li><p>Andersen, LP, et al., &amp; Gögenur, I (2016). Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. <i>BMC pharmacology &amp; toxicology</i> 17 8–None. DOI:<a href=&quot;https://doi.org/10.1186/s40360-016-0052-2&quot;>10.1186/s40360-016-0052-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26893170/&quot;>https://pubmed.ncbi.nlm.nih.gov/26893170</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05CH01_1;
